selinexor + momelotinib

Selinexor + momelotinib is an investigational **combination therapy** of two small-molecule oral drugs with distinct but potentially complementary mechanisms. **Selinexor** is an inhibitor of *exportin 1 (XPO1)*, a nuclear export protein. By blocking XPO1, selinexor leads to nuclear retention and activation of tumor suppressor proteins, inhibiting cancer cell survival, and can downregulate pro-proliferative and anti-apoptotic pathways. **Momelotinib** is an inhibitor of *Janus kinase 1 (JAK1)*, *Janus kinase 2 (JAK2)*, and *activin A receptor type 1 (ACVR1/ALK2)*, targeting pathways important in inflammatory signaling and myeloproliferative neoplasms. This combination is being explored preclinically for synergistic antiproliferative effects in **myelofibrosis** and other malignancies, as both agents affect independent but overlapping pathways that drive disease pathogenesis. Studies show selinexor and momelotinib together yield enhanced inhibition of cell growth in myeloproliferative neoplasm cell lines, supporting its potential as a novel regimen in myelofibrosis therapy[3].